ICB-PHARMA 2021 - The 4th International Conference Current Breakthrough in Pharmacy

Introduction

Welcome to the fourth International Conference of Current Breakthrough in Pharmacy. This year, our conference will be held virtually by Zoom Conference.
The 4th ICB-Pharma (The 4th International Conference Current Breakthrough in Pharmacy) invites all potential authors from universities and various organisations to submit papers in the area of pharmacy. This conference is part of a conference program called International Summit on Science Technology and Humanity (ISETH) 2021 Organized by Universitas Muhammadiyah Surakarta.

Theme

Pharmaceutical Development in the post-Covid-19 Era

Speakers

Invited Speakers

Focus and Scope

 

Pharmaceutics and Applied Materials for Drug Delivery
Pharmacology and Toxicology
Pharmacy Practices and Clinical Pharmacy
Medicinal and Pharmaceutical Chemistry
Pharmacognosy & Ethnobotany
Biotechnology and Microbiology

Important Dates

Collaborations

The 4th International Current Breakthrough in Pharmacy
Conference Chair: Peni Indrayudha, S.F, M.Biotech, Apt, Ph.D.

Track 1: Pharmaceutics and Applied Materials for Drug Delivery

Track Director: Anita Sukmawati, S.Si., Apt., M.Si., Ph.D.

• Physical pharmacy • pharmaceutics • pharmaceutical technology • drug delivery • pharmaceutical engineering • materials science • nanotechnology • novel development in manufacturing • concept of Quality by Design in pharmaceutical product

Track 2: Pharmacology and Toxicology

Track Director: Zakky Cholisoh, S.Si., M.Clin.Pha, Ph.D.

• Experimental animal pharmacology and toxicology • biochemical cellular pharmacology and toxicology • pharmacokinetics • pharmacodynamics, computational prediction of pharmacology • randomised controlled trial • pharmacogenetics • and all aspects of microbiology.

Track 3: Pharmacy Practices and Clinical Pharmacy

Track Director: Hidayah Karuniawati, S.Farm., M.Sc., Apt.

• Social Pharmacy • Pharmacoeconomics • Pharmacoepidemiology • Pharmacy Management • Pharmacy Practice • Health Related Quality of Life Studies • Hospital pharmacy • Community pharmacy • Public health pharmacy • Clinical medicines • Medication counseling • Therapeutic drug monitoring • Parenteral nutrition • Ambulatory care pharmacy • Oncology pharmacy.

Track 4: Medicinal and Pharmaceutical Chemistry

Track Director: Ika Trisharyanti Dian Kusumowati, S.Si, M.Farm, Apt.

• Pharmaceutical Analysis • Environmental Analysis • Biomedical and Biomolecular Analysis • Analytical instrumentation and Methods • Food Analysis • Biosensor, Biochemistry • Medicinal Chemistry.

Track 5: Pharmacognosy & Ethnobotany

Track Director: Rima Munawaroh, S.Si., M.Sc, Apt.

• The structural and chemical characterization • the metabolic pathways leading to the synthesis of pharmacologically active compounds • the significance of natural substances in pharmaceutical research • the introducing different ways of applying plant drugs • the effect and use of drugs, herbal extracts and isolated compounds • the collection and cultivation of medicinal plants • breeding strategies and the application of biotechnology • traditional plant usage for food and fodder plants • medicinal plants • fibers and dyeing plants •   the use herbs to treat illness or applying them in a variety of ways.

Track 6: Biotechnology and Microbiology

Track Director: Maryati, M.Si, Ph.D, S.Si, Apt

• Angiogenesis • invasion and metastasis • antiproliferative • cell cycle • apoptosis • anticancer • immunomodulator • antioxidant • immunotherapy • chemotherapy • carcinogenesis • cancer stem cell • molecular docking • molecular oncology • cancer metabolism • cancer immunology • cancer pharmacogenomic and pharmacogenetic • diagnostics • pharmacotherapy • pharmacoepidemiology • nutraceuticals • cosmeceuticals.

Ethical guidelines for journal publication

Publisher is committed to ensuring ethics in publication and quality of articles.
Conformance to standards of ethical behavior is therefore expected of all parties involved: Authors, Editors, Reviewers, and the Publisher.

In particular,
Authors: Authors should present an objective discussion of the significance of research work as well as sufficient detail and references to permit others to replicate the experiments. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable. Review articles should also be objective, comprehensive, and accurate accounts of the state of the art. The authors should ensure that their work is entirely original works, and if the work and/or words of others have been used, this has been appropriately acknowledged. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. Authors should not submit articles describing essentially the same research to more than one journal. The corresponding author should ensure that there is a full consensus of all co-authors in approving the final version of the paper and its submission for publication.

Editors: Editors should evaluate manuscripts exclusively on the basis of their academic merit. An editor must not use unpublished information in the editor's own research without the express written consent of the author. Editors should take reasonable responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper.

Reviewers: Any manuscripts received for review must be treated as confidential documents. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviews should be conducted objectively, and observations should be formulated clearly with supporting arguments, so that authors can use them for improving the paper. Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers

Article withdraw policy
It is a general principle of scholarly communication that the editor/guest editor of a learned journal/series is solely and independently responsible for deciding which articles submitted to the journal shall be published. In making this decision the editor/guest editor is guided by policies of the journal's editorial board and constrained by such legal requirements in force regarding libel, copyright infringement and plagiarism. An outcome of this principle is the importance of the scholarly archive as a permanent, historic record of the transactions of scholarship. Articles that have been published shall remain extant, exact and unaltered as far as is possible. However, very occasionally circumstances may arise where an article is published that must later be retracted or even removed. Such actions must not be undertaken lightly and can only occur under exceptional circumstances, such as:

Article Withdrawal:
Only used for Articles in Press which represent early versions of articles and sometimes contain errors, or may have been accidentally submitted twice. Occasionally, but less frequently, the articles may represent infringements of professional ethical codes, such as multiple submission, bogus claims of authorship, plagiarism, fraudulent use of data or the like.
Article Retraction:
Infringements of professional ethical codes, such as multiple submission, bogus claims of authorship, plagiarism, fraudulent use of data or the like. Occasionally a retraction will be used to correct errors in submission or publication.
Article Removal:
Legal limitations upon the publisher, copyright holder or author(s).
Article Replacement:
Identification of false or inaccurate data that, if acted upon, would pose a serious health risk.

The 4th International Current Breakthrough in Pharmacy (ICB-Pharma) 2021 implements a peer-review policy of single-blind review, where each paper will be evaluated and reviewed in layers. The proceedings editor will evaluate the submitted paper to determine its suitability with the conference focus and scope. Once the paper is declared accepted by the committee, it is sent to two independent expert reviewers. Their role is to review and recommend whether the paper is suitable enough to be published by the Atlantis Press. After going through all these processes and declared recommendations by reviewers, the paper can be submitted to Atlantis Press for publication.